Effects of Teriparatide on Treatment Outcomes in Osteoporotic Hip and Pelvic Bone Fractures: Meta-analysis and Systematic Review of Randomized Controlled Trials
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The primary objective of this study was to evaluate randomized controlled trials (RCTs) that have reported the effects of teriparatide on bone-healing in osteoporotic hip and pelvic bone fractures to determine the efficacy of teriparatide in lowering the rate of treatment failure. A total of 2,809 studies were identified using a comprehensive literature search (MEDLINE [n=1,061], Embase [n=1,395], and Cochrane Library n=353]). Five RCTs were included in the final analysis. Treatment failure rates at the last follow-up of osteoporotic hip and pelvic bone fractures between the teriparatide and control groups was the primary outcome. Treatment failure was defined as non-union, varus collapse of the proximal fragment, perforation of the lag screw, and any revision in cases due to mechanical failure of the implant during the follow-up period. The number of treatment failures in the teriparatide and placebo groups were 11.0% (n=20 out of 181) and 17.6% (n=36 out of 205), respectively. Although the rate of treatment failure in the teriparatide group was lower than that in the control group, this difference was not significant (odds ratio, 0.81 [95% confidence interval, 0.42-1.53]; P=0.16; I2=42%). This metaanalysis did not identify any significant differences in the rate of treatment failure between the teriparatide and control groups at final follow-up. Based on these results, we believe that there is a lack of evidence to confirm efficacy of teriparatide in reducing treatment failures in osteoporotic hip and pelvic bone fractures.
Abstract
The primary objective of this study was to evaluate randomized controlled trials (RCTs) that have reported the effects of teriparatide on bone-healing in osteoporotic hip and pelvic bone fractures to determine the efficacy of teriparatide in lowering the rate of treatment failure. A total of 2,809 studies were identified using a comprehensive literature search (MEDLINE [n=1,061], Embase [n=1,395], and Cochrane Library n=353]). Five RCTs were included in the final analysis. Treatment failure rates at the last follow-up of osteoporotic hip and pelvic bone fractures between the teriparatide and control groups was the primary outcome. Treatment failure was defined as non-union, varus collapse of the proximal fragment, perforation of the lag screw, and any revision in cases due to mechanical failure of the implant during the follow-up period. The number of treatment failures in the teriparatide and placebo groups were 11.0% (n=20 out of 181) and 17.6% (n=36 out of 205), respectively. Although the rate of treatment failure in the teriparatide group was lower than that in the control group, this difference was not significant (odds ratio, 0.81 [95% confidence interval, 0.42-1.53]; P=0.16; I2=42%). This metaanalysis did not identify any significant differences in the rate of treatment failure between the teriparatide and control groups at final follow-up. Based on these results, we believe that there is a lack of evidence to confirm efficacy of teriparatide in reducing treatment failures in osteoporotic hip and pelvic bone fractures.
참고문헌 (34)
- Ha YC, "Current trends and future projections of hip fracture in South Korea using nationwide claims data", Osteoporos Int, 27, pp.2603~2609 (2016)
- 하용찬, "Trend in Hip Fracture Incidence and Mortality in Korea: A Prospective Cohort Study from 2002 to 2011", Journal of Korean Medical Science, 30(4), pp.483~488 (2015), 대한의학회
- Nakano T, "Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks : subgroup analysis of the Teriparatide Once-Weekly Efficacy Research(TOWER)trial", J Bone Miner Metab, 32, pp.441~446 (2014)
- Sugimoto T, "Vertebral fracture risk after once-weekly teriparatide injections : follow-up study of Teriparatide Once-Weekly Efficacy Research(TOWER)trial", Curr Med Res Opin, 29, pp.195~203 (2013)
- Once-Weekly Efficacy Research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk, "J Clin Endocrinol Metab", 2012, 3097~3106
- Shiraki M, "Treatment responses with once-weekly teriparatide therapy for osteoporosis", Osteoporos Int, 27, pp.3057~3062 (2016)
- Liu Y, "Anabolic agents: what is beyond osteoporosis?", Osteoporos Int, 29, pp.1009~1022 (2018)
- Lau EMC, "Romosozumab or alendronate for fracture prevention in East Asian patients : a subanalysis of the phase III, randomized ARCH study", Osteoporos Int, 31, pp.677~685 (2020)
- Takada J, "Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide : a post hoc analysis of the STRUCTURE trial", J Bone Miner Metab, 38, pp.310~315 (2020)
- Kanezaki S, "Enhancement of the effects of intermittent parathyroid hormone(1-34)by bone morphogenetic protein in a rat femoral open fracture model", J Orthop Surg Res, 14, pp.403~ (2019)
- Zandi M, "Histological assessment of the effects of teriparatide therapy on mandibular fracture healing : a preclinical study", J Craniomaxillofac Surg, 48, pp.211~216 (2020)
- Tsubouchi Y, "Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model", J Orthop Surg Res, 13, pp.267~ (2018)
- Shi Z, "Effectiveness of teriparatide on fracture healing : a systematic review and meta-analysis", PLoS One, 11, pp.e0168691~ (2016)
- Shin WC, "A retrospective bicenter comparative study of surgical outcomes of atypical femoral fracture : potential effect of teriparatide on fracture healing and callus formation", Bone, 128, pp.115033~ (2019)
- Yoo JI, "Teriparatide treatment in elderly patients with sacral insufficiency fracture", J Clin Endocrinol Metab, 102, pp.560~565 (2017)
- 김정택, "Adjuvant Teriparatide Therapy for Surgical Treatment of Femoral Fractures; Does It Work?", Hip and Pelvis, 28(3), pp.148~156 (2016), 대한고관절학회[DOI]
- Oba H, "Weekly teriparatide versus bisphosphonate for bone union during 6 months after multi-level lumbar interbody fusion for osteoporotic patients : a multicenter, prospective, randomized study", Spine(Phila Pa 1976), 45, pp.863~871 (2020)
- Bhandari M, "Does teriparatide improve femoral neck fracture healing : results from a randomized placebo-controlled trial", Clin Orthop Relat Res, 474, pp.1234~1244 (2016)
- Aspenberg P, "Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture : results of a randomized, active-controlled, double-blind clinical trial at 26 weeks", J Bone Joint Surg Am, 98, pp.1868~1878 (2016)
- Chesser TJ, "The administration of intermittent parathyroid hormone affects functional recovery from trochanteric fractured neck of femur : a randomised prospective mixed method pilot study", Bone Joint J, 98, pp.840~845 (2016)
- Wang YK, "Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis : a meta-analysis of randomized controlled trials", Medicine(Baltimore), 96, pp.e6970~ (2017)
- Yang C, "Effects of teriparatide compared with risedronate in the treatment of osteoporosis : a metaanalysis of randomized controlled trials", Medicine(Baltimore), 99, pp.e19042~ (2020)
- Sheehan KJ, "Mortality by timing of hip fracture surgery : factors and relationships at play", J Bone Joint Surg Am, 99, pp.e106~ (2017)
- Katsoulis M, "Excess mortality after hip fracture in elderly persons from Europe and the USA : the CHANCES project", J Intern Med, 281, pp.300~310 (2017)
- Huang TW, "Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures", Medicine(Baltimore), 95, pp.e3626~ (2016)
- Peichl P, "Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women", J Bone Joint Surg Am, 93, pp.1583~1587 (2011)
- Kanakaris NK, "Enhancement of hip fracture healing in the elderly : evidence deriving from a pilot randomized trial", Injury, 46, pp.1425~1428 (2015)
- "Cochrane handbook for systematic reviews of interventions: version 5.1.0" (2011)[URL]
- Rhee SJ, "A comparison of long-term outcomes of computer-navigated and conventional total knee arthroplasty : a meta-analysis of randomized controlled trials", J Bone Joint Surg Am, 101, pp.1875~1885 (2019)
- Lou S, "Parathyroid hormone analogues for fracture healing : protocol for a systematic review and meta-analysis of randomised controlled trials", BMJ Open, 8, pp.e019291~ (2018)
- Lou S, "The effect of teriparatide on fracture healing of osteoporotic patients : a meta-analysis of randomized controlled trials", Biomed Res Int, 2016, pp.6040379~ (2016)
- Díez-Pérez A, "Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis : a systematic review and meta-analysis", Bone, 120, pp.1~8 (2019)
- Johansson T, "PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients", Acta Orthop, 87, pp.79~82 (2016)
- Aspenberg P, "Teriparatide improves early callus formation in distal radial fractures", Acta Orthop, 81, pp.234~236 (2010)